Real-World Evalua�on of Treatment Patern, Time to Next Treatment, Healthcare Resource U�liza�on,and Cost of Care in Follicular Lymphoma
Sameh Gaballa*1, Mei Xue2, Po-Ya Chuang3, Kaitlyn Esselman4, Wesley Furnback4, Keri Yang2
1Moffitt Cancer Center, Tampa, FL, United States of America, 2BeiGene USA, Inc., San Mateo, CA, UnitedStates of America, 3Real Chemistry, Inc., San Francisco, California, United States of America, 4RealChemistry, Inc., New York, United States of America

Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma andaccounts for nearly a quarter of cases. As a heterogenous disease, with an es�mated 20% of pa�ents
having disease progression within 24 months of the ﬁrst line of therapy, FL o�en quickly becomes
relapsed or refractory to the current treatment.
Aims: This study aimed to evaluate the real-world treatment paterns, �me to next treatment (TTNT),and associated costs and healthcare resource u�liza�on (HCRU) in pa�ents with FL in the United States.
Methods: A retrospec�ve study was conducted using Optum® Clinforma�cs® Data Mart to iden�fypa�ents ≥18 years with ≥1 diagnosis for FL ini�a�ng 1L, 2L, 3L, or 4L treatment from 1/2019 to 02/2023.
Pa�ents were required to be con�nuously enrolled for 30 days pre- and post-index date, deﬁned as thedate of treatment ini�a�on. Pa�ents were categorized into mutually exclusive cohorts based ontreatment regimen. TTNT was measured for pa�ents who had a subsequent treatment within the study
period. Total cost of care included both plan- and pa�ent-paid claims, adjusted for inﬂa�on (2023 USD).
HCRU included outpa�ent visits and inpa�ent admissions. Costs and HCRU were reported per pa�ent permonth over the treatment dura�on.
Results: There were 4,525 pa�ents ini�a�ng 1L treatment and 1,053, 304, and 97 pa�ents ini�a�ng 2L,3L, and 4L treatment, respec�vely. Median follow-up was 487 days (1L), 430 days (2L), 357 days (3L), and276 days (4L). The mean age at the index was similar across cohorts (range: 69.6 [1L] to 71.9 [4L]).
Rituximab monotherapy (R-mono) was the most u�lized treatment in 1L and 2L, followed bybendamus�ne + rituximab (BR) and R-CHOP (Table). Lenalidomide + rituximab (R2) was the most u�lizedregimen in 3L and 4L. Obinutuzumab monotherapy (O-mono) use increased by line of therapy. The
median TTNT across all regimens decreased by line of therapy (Table). BR and bendamus�ne +obinutuzumab (BO) had longer TTNT in 1L, while BR and R2 had longer TTNT in 3L. Inpa�ent admissions
and outpa�ent visits increased with the line of therapy. Mean (SD) outpa�ent visits were 5.3 (3.2) in 1L,5.8 (3.7) in 2L, 6.3 (4.0) in 3L, and 6.1 (3.3) in 4L, while inpa�ent admissions ranged from 0.1 (0.3) in 1L to0.3 (0.4) in 4L. The mean total cost of care ranged from $40,538-$74,466, increasing by line of therapy.
The mean total cost of care was consistently lowest in R-mono ($31,704-$36,197), while CAR-T had thehighest total cost ($501,493-$522,378). R-mono had the lowest while R-CHOP had the highest meanoutpa�ent visits across lines of therapy.
Summary/Conclusion: Real-world TTNT decreased while costs and HCRU increased with eachsubsequent line of treatment, indica�ng a high disease burden in FL pa�ents, par�cularly for those withR/R FL. These ﬁndings suggest the need for beter treatment op�ons for pa�ents with FL, especially in 3Land 4L.

EHA 2024

EHA 2024